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Angiogenesis is a tightly regulated process in vertebrates that leads to the formation of new blood vessels 
from pre-existing vessels or by the recruitment of bone marrow–derived endothelial precursor cells[1]. 
During embryogenesis, after stimulation by proangiogenic factors, such as VEGF or FGF, it contributes 
to the maturation of the vascular plexus. In adults, it is important in some physiologic conditions, such as 
wound healing or the reproductive cycle in females, although most of the time it is “switched off” by 
endogenous inhibitors, such as endostatin or angiostatin. Furthermore, its misregulation is the cause of 
many pathological situations, as it contributes to tumor development[2], diabetic retinopathy[3], 
rheumatoid arthritis[4], psoriasis[5], but also cardiovascular disorders[6] and obesity[7].  
Although integrins are considered the main matrix adhesion proteins, recent evidence demonstrates an 
important role for the syndecans in the regulation of this function and for the integration of the 
extracellular signals from the environment that gives the adequate responses through the modulation of 
the cytoskeleton[8]. Syndecans are integral transmembrane proteins that belong to the heparan sulfate 
proteoglycan (HSPG) superfamily. They are known to bind a wide range of ligands, from growth factors 
to extracellular matrix proteins, due to the high negative charge of the glycosaminoglycan chains they 
bear[9]. The importance is clear, since all eukaryotic cells express at least one of the four members 
(syndecans 1–4) described until now. All syndecans share high homology, mainly in the cytoplasmic 
domain, although they have different ectodomains, which suggests that they have evolved to carry out 
similar, but nonidentical functions[9,10]. They have been implicated as coreceptors for growth factors[11] 
in cell-cell[12] and cell-matrix adhesion[13]. However, the involvement of each syndecan in different 
diseases has only recently been elucidated.  
Syndecan-2, identified in fibroblasts, is also the main HSPG expressed by endothelial cells[14]. It has 
been directly involved in some tumor-related processes[15,16,17], but the most specific function 
attributed to this proteoglycan is the crucial role that it plays in endogenous fibronectin 
fibrillogenesis[18], a process involved in the development of fibrotic diseases[19]. Its participation in 
angiogenesis has also been suggested, since it is essential for new blood vessel sprouting during zebrafish 
embryogenesis[20] and its down-regulation in mouse endothelial cells reduces the formation of capillary-
like structures[21]. In a recent article published in Experimental Cell Research, we demonstrated that 
syndecan-2 plays a central role in many steps of human “in vitro” neovascularization[22]. 
Previous work on syndecan-2 has focused on its intracellular binding partners and its participation in 
some basic events in different cellular models. It has been involved in adhesion events and actin 
cytoskeleton organization, as different groups demonstrated the interaction of the cytoplasmic tail of 
syndecan-2 with proteins such as synbindin[23], syntenin[24], and CASK[25]. In our lab, we have 




described the interaction of the PDZ protein Ezrin with the proximal part of the cytoplasmic domain of 
syndecan-2, and that its overexpression in COS cells induces filopodia through cdc42 activation[26]. We 
also described how its overexpression in epithelial cells induces a migratory phenotype[27] and stimulates 
the proliferation in Swiss 3T3 fibroblasts[28]. In addition, other researchers found the same results on 
colon carcinoma cells[16,17].  
In our last study, by down-regulation of syndecan-2 expression with phosphorothioate antisense 
oligonucleotides in a human endothelial microvascular cell model, we demonstrated its involvement in 
different cellular functions related to angiogenic processes[22]. We showed that it decreases the spreading 
and adhesion of these cells when seeded on fibronectin, increased its migration, but impaired the 
formation of capillary-like structures in matrigel. Additional experiments also demonstrated that the 
inhibition of this proteoglycan decreased and reorganized the focal adhesions, as shown by paxillin 
immunostaining, while increasing the stress fibers assembly (Fig. 1). This is consistent with a migratory 
phenotype, but also with an impairment of the endothelial morphogenesis into tubular structures[29].  
 
FIGURE 1. Syndecan-2 down-regulation redistributed the focal contacts and the actin 
cytoskeleton. HMEC-1 cells were transfected with the oligonucleotides AS2 and ASMis, 
and after 24 h in culture, were immunostained with paxillin mAb (focal contacts, green) 
and phalloidin (actin cytoskeleton, red). As shown, paxillin staining decreased and 
reorganized, while the stress fibers became prominent, typical of a migratory phenotype. 
One of three independent experiments is shown. (n = 3).  
We also demonstrated that syndecan-2 protein expression is specifically regulated by well-known 
proangiogenic growth factors, such as FGF or VEGF, and also different matrices, such as fibronectin or 
collagen, both in two- or three-dimensional culture conditions. Typically, an enrichment in fibronectin is 
seen under wound healing conditions, and laminin and collagen deposition has been described for certain 
tumors[30,31]. As these processes are also characterized by an enhanced release of growth factors and 




both conditions are able to induce syndecan-2 expression, these proteoglycans may play a pivotal role in 
giving the adequate response in each situation.  
Evidence for integrin and syndecan cooperation in signaling events has become clear in recent 
years[8], since the regulation of the αvβ3 and αvβ5 integrins by syndecan-1 during angiogenesis has been 
demonstrated[32], as well as the interaction with Mac-1[33]. Furthermore, syndecan-2 is able to interact 
with α5β1 integrin in the regulation of stress fiber formation[34], and with α2 integrin[35] in the control of 
adhesion and migration. On the other hand, syndecan-2 has also been involved in signaling processes, as 
in the phosphorylation of FAK[36] or in the activation of src, when this proteoglycan is in complex with 
p120-GAP[37].  
Taking all these considerations together with our results that demonstrated the involvement of 
syndecan-2 in most of the basic events that take place during neovascularization in endothelial cells 
cultured “in vitro”[22], we propose a role for this proteoglycan as an adaptor protein that is able to 
integrate different environmental signals essential to induce the angiogenic switch through the regulation 
of its expression, and a key element in cooperation with the integrins in order to induce cytoskeleton 
reorganization necessary for capillary morphogenesis. 
Although its importance has not been fully elucidated, as it may also be needed in other processes, 
such as matrix degradation by metalloproteases or in apoptosis, our work helps to clarify the role of this 
heparan sulfate proteoglycan in the biology of endothelial cells. Further “in vivo” experiments may 
determine if it would be a good target for antiangiogenic therapies, one of the most promising antitumor 
strategies[38], but also for many other diseases. 
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